FAKTOR-OPTIONSSCHEIN - BIOMERIEUX Share Price

Certificat

DE000MG2XA63

Market Closed - Börse Stuttgart 08:30:46 31/05/2024 pm IST
5.44 EUR +15.25% Intraday chart for FAKTOR-OPTIONSSCHEIN - BIOMERIEUX
Current month-50.68%
1 month-50.68%
Date Price Change
31/24/31 5.44 +15.25%
30/24/30 4.72 +3.51%
29/24/29 4.56 -7.13%
28/24/28 4.91 -3.54%
27/24/27 5.09 -4.50%

Delayed Quote Börse Stuttgart

Last update May 31, 2024 at 08:30 pm IST

More quotes

Static data

Product typeExotic Products
Buy / SellCALL
Underlying BIOMÉRIEUX
Issuer Morgan Stanley
WKN MG2XA6
ISINDE000MG2XA63
Date issued 24/04/2024
Strike 82.62
Maturity Unlimited
Parity 2.49 : 1
Emission price 10
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 10.6
Lowest since issue 4.35
Spread -0.37
Spread %6.75%

Company Profile

bioMérieux designs, develops, produces, and sells systems used in clinical practice to diagnose infectious diseases (including HIV, tuberculosis, and respiratory infections), cancers, and cardiovascular pathologies based on a biological sample (blood, saliva, urine, etc.). Net sales break down by sector of application as follows: - medical applications (84.4%): in industry, microbiological testing of samples from finished products, materials during the manufacturing process, or the environment, primarily in the food-processing, pharmaceutical, and cosmetics sectors; - industrial applications (15.6%). The group's diagnostic systems consist of three elements with related services: reagents, instruments (or platforms or analyzers), software, and services. Net sales are distributed geographically as follows: Europe/Middle East/Africa (32.4%), North America (44.1), Asia/Pacific (17.3%) and Latin America (6.2%).
Sector
-
More about the company

Ratings for bioMérieux

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: bioMérieux

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
97.15 EUR
Average target price
114.2 EUR
Spread / Average Target
+17.52%
Consensus